Rolapitant (Varubi)

General information

Class/mechanism: Substance P/neurokinin 1 (NK1) receptor antagonist.
Route: PO
Extravasation: n/a

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.

History of changes in FDA indication

• 9/1/2015: Initial FDA approval "in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting sssociated with initial and repeat courses of emetogenic cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy."

Also known as

SCH619734, SCH-619734